v3.25.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
Summary Compensation Table Total for PEO
($)(1)
Compensation Actually Paid to PEO
($)(2)
Average Summary Compensation Table Total for Non-PEO NEOs
($)(1)
Average Compensation Actually Paid to Non-PEO NEOs
($)(2)
Value of Initial Fixed $100 Investment Based On:
Net Income (Loss)
($ in thousands)(4)
Total Revenues
($ in thousands)(5)
Year
TSR
($)(3)
Peer Group TSR
($)(3)
202415,527,46417,262,0154,695,6355,200,14682.50118.20560,1204,068,950
2023
15,341,235(2,503,427)4,231,034208,19382.40118.87414,8323,834,204
2022
17,325,61826,315,0055,035,5097,254,180106.72113.65(224,060)3,659,374
2021
15,679,3114,921,2384,544,6132,655,06385.34126.45(329,668)3,094,238
202012,573,30019,597,6594,091,3036,154,655110.56126.42238,6162,363,567
        
Company Selected Measure Name total revenues        
Named Executive Officers, Footnote For each FY, represents amount reported for our PEO and average amount reported for our non-PEO NEOs, in each case in the Total column of the Summary Compensation Table. Our PEO and our non-PEO NEOs for each of the applicable years were as follows:
YearPEONon-PEO NEOs
2024Bruce C. CozaddRenee Gala, Patricia Carr, Robert Iannone, Philip Johnson and Samantha Pearce
2023Bruce C. CozaddRenee Gala, Patricia Carr, Robert Iannone, Neena Patil, Daniel N. Swisher, Jr. and Kim Sablich
2022Bruce C. Cozadd
Daniel N. Swisher, Jr., Renee Gala, Robert Iannone and Kim Sablich
2021Bruce C. Cozadd
Daniel N. Swisher, Jr., Renee Gala, Robert Iannone and Chris Tovey
2020Bruce C. Cozadd
Daniel N. Swisher, Jr., Renee Gala, Robert Iannone and Kim Sablich
        
Peer Group Issuers, Footnote For the relevant fiscal year, represents the cumulative TSR of our ordinary shares and the NASDAQ Biotechnology Index at the end of each fiscal year. In each case, assume an initial investment of $100 on December 31, 2019, and reinvestment of dividends, if any.        
PEO Total Compensation Amount $ 15,527,464 $ 15,341,235 $ 17,325,618 $ 15,679,311 $ 12,573,300
PEO Actually Paid Compensation Amount $ 17,262,015 (2,503,427) 26,315,005 4,921,238 19,597,659
Adjustment To PEO Compensation, Footnote Amounts represent Compensation Actually Paid to our PEO and the average Compensation Actually Paid to our non-PEO NEOs for the relevant fiscal year. Compensation Actually Paid represents the amount reported in the Total column of the Summary Compensation Table for the applicable FY, adjusted as shown below. For the purposes of the below adjustments, the fair value of equity awards on the applicable date were determined in accordance with FASB ASC 718, using valuation methodologies that are generally consistent with those used to determine the grant-date fair value for accounting purposes. Fair value or change in fair value, as applicable, of equity awards in the Compensation Actually Paid columns was determined as follows: (i) for RSUs, the closing price of our ordinary shares on the applicable fiscal year-end date, or, in the case of vesting RSUs, the closing price of our ordinary shares on the applicable vesting date; (ii) for PSUs, the closing fair value of the awards using a Monte-Carlo simulation method, multiplied by a factor reflecting achievement of the probable outcome of the cumulative performance objective as of the measurement date; and (iii) for stock options, the closing fair value of the stock options based on a Black-Scholes option pricing model on the applicable fiscal year-end date, or, in the case of vesting stock options, the closing fair value on the applicable vesting date. Details of the adjustments made to the Summary Compensation Table are as follows:
2024
AdjustmentsPEO
($)		Average Non-PEO NEOs
($)
Total compensation as reported in the Summary Compensation Table15,527,4644,695,635
(Deduct): Grant date fair value of awards as reported in the Stock Awards column in the Summary Compensation Table for current FY(12,799,687)(3,439,493)
Add: ASC 718 fair value of awards granted during applicable fiscal year that remain unvested as of current fiscal year-end, determined as of applicable fiscal year-end14,526,7563,926,373
Add: Change in ASC 718 fair value from prior fiscal year-end to current fiscal year-end of awards granted during prior FYs that were outstanding and unvested as of applicable fiscal year-end331,88364,690
Add: Change in ASC 718 fair value from prior fiscal year-end to vesting date of awards granted during prior fiscal years that vested during current fiscal year(324,401)(47,059)
Total Adjustments1,734,551504,511
Compensation Actually Paid17,262,0155,200,146
        
Non-PEO NEO Average Total Compensation Amount $ 4,695,635 4,231,034 5,035,509 4,544,613 4,091,303
Non-PEO NEO Average Compensation Actually Paid Amount $ 5,200,146 208,193 7,254,180 2,655,063 6,154,655
Adjustment to Non-PEO NEO Compensation Footnote Amounts represent Compensation Actually Paid to our PEO and the average Compensation Actually Paid to our non-PEO NEOs for the relevant fiscal year. Compensation Actually Paid represents the amount reported in the Total column of the Summary Compensation Table for the applicable FY, adjusted as shown below. For the purposes of the below adjustments, the fair value of equity awards on the applicable date were determined in accordance with FASB ASC 718, using valuation methodologies that are generally consistent with those used to determine the grant-date fair value for accounting purposes. Fair value or change in fair value, as applicable, of equity awards in the Compensation Actually Paid columns was determined as follows: (i) for RSUs, the closing price of our ordinary shares on the applicable fiscal year-end date, or, in the case of vesting RSUs, the closing price of our ordinary shares on the applicable vesting date; (ii) for PSUs, the closing fair value of the awards using a Monte-Carlo simulation method, multiplied by a factor reflecting achievement of the probable outcome of the cumulative performance objective as of the measurement date; and (iii) for stock options, the closing fair value of the stock options based on a Black-Scholes option pricing model on the applicable fiscal year-end date, or, in the case of vesting stock options, the closing fair value on the applicable vesting date. Details of the adjustments made to the Summary Compensation Table are as follows:
2024
AdjustmentsPEO
($)		Average Non-PEO NEOs
($)
Total compensation as reported in the Summary Compensation Table15,527,4644,695,635
(Deduct): Grant date fair value of awards as reported in the Stock Awards column in the Summary Compensation Table for current FY(12,799,687)(3,439,493)
Add: ASC 718 fair value of awards granted during applicable fiscal year that remain unvested as of current fiscal year-end, determined as of applicable fiscal year-end14,526,7563,926,373
Add: Change in ASC 718 fair value from prior fiscal year-end to current fiscal year-end of awards granted during prior FYs that were outstanding and unvested as of applicable fiscal year-end331,88364,690
Add: Change in ASC 718 fair value from prior fiscal year-end to vesting date of awards granted during prior fiscal years that vested during current fiscal year(324,401)(47,059)
Total Adjustments1,734,551504,511
Compensation Actually Paid17,262,0155,200,146
        
Compensation Actually Paid vs. Total Shareholder Return
4999
        
Compensation Actually Paid vs. Net Income
5001
        
Compensation Actually Paid vs. Company Selected Measure
5003
        
Total Shareholder Return Vs Peer Group
4999
        
Tabular List, Table Total Revenues
•Revenue (product- / therapeutic area-specific)
•Non-GAAP Adjusted Operating Margin
•Relative TSR
•Pipeline Progression
•Regulatory Advancement
        
Total Shareholder Return Amount $ 82.50 82.40 106.72 85.34 110.56
Peer Group Total Shareholder Return Amount 118.20 118.87 113.65 126.45 126.42
Net Income (Loss) $ 560,120,000 $ 414,832,000 $ (224,060,000) $ (329,668,000) $ 238,616,000
Company Selected Measure Amount 4,068,950,000 3,834,204,000 3,659,374,000 3,094,238,000 2,363,567,000
PEO Name Bruce C. Cozadd Bruce C. Cozadd Bruce C. Cozadd Bruce C. Cozadd Bruce C. Cozadd
Additional 402(v) Disclosure
The disclosure included in this section is prescribed by SEC rules and does not necessarily align with how we or our Compensation Committee view the link between our performance and NEO pay. For additional information about our pay-for-performance philosophy and how we align executive compensation our Company performance, refer to the “Executive Compensation—Compensation Discussion and Analysis” section above.
Required Tabular Disclosure of Pay Versus Performance
The table below reflects information regarding the compensation of our NEOs for fiscal years 2024, 2023, 2022, 2021 and 2020, as well as our financial performance for each of these FYs in accordance with SEC rules. The amounts set forth below under the headings “Compensation Actually Paid to PEO” and “Average Compensation Actually Paid to Non-PEO NEOs” have been calculated in a manner consistent with Item 402(v) of Regulation S-K. Use of the term “compensation actually paid” is required by the SEC’s rules and as a result of the calculation methodology required by the SEC, such amounts differ from compensation actually received by the individuals and the compensation decisions described in the “Executive Compensation—Compensation Discussion and Analysis” section above.
The amounts represent the net income (loss) as reported in our audited financial statements for the applicable fiscal year.As required by Item 402(v) of Regulation S-K, we have determined that the Company-Selected Measure is total revenues as reported in our audited financial statements for the applicable fiscal year.
The most important financial and non-financial performance measures used by us to link compensation actually paid to our NEOs for the most recently completed fiscal year to our performance are set forth below. For further information regarding these performance metrics and their function in our executive compensation program, please see “Executive Compensation—Compensation Discussion and Analysis” above.
As required by Item 402(v) of Regulation S-K, we are providing the following graphs to illustrate the relationship between the pay and performance figures that are included in the pay versus performance tabular disclosure above. In addition, the first graph below further illustrates the relationship between company TSR and that of the NASDAQ Biotechnology Index. As noted above, compensation actually paid for purposes of the tabular disclosure and the following graphs were calculated in accordance with SEC rules and do not fully represent the actual final amount of compensation earned by or actually paid to our NEOs during the applicable years.
All information provided above under the “Item 402(v) Pay Versus Performance” heading will not be deemed to be incorporated by reference into any filing by us under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent we specifically incorporate such information by reference.
        
Measure:: 1          
Pay vs Performance Disclosure          
Name Total Revenues        
Measure:: 2          
Pay vs Performance Disclosure          
Name Revenue (product- / therapeutic area-specific)        
Measure:: 3          
Pay vs Performance Disclosure          
Name Non-GAAP Adjusted Operating Margin        
Measure:: 4          
Pay vs Performance Disclosure          
Name Relative TSR        
Measure:: 5          
Pay vs Performance Disclosure          
Name Pipeline Progression        
Measure:: 6          
Pay vs Performance Disclosure          
Name Regulatory Advancement        
PEO [Member] | Equity Awards Adjustments          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 1,734,551        
PEO [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (12,799,687)        
PEO [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 14,526,756        
PEO [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (324,401)        
PEO [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 331,883        
Non-PEO NEO [Member] | Equity Awards Adjustments          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 504,511        
Non-PEO NEO [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (3,439,493)        
Non-PEO NEO [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 3,926,373        
Non-PEO NEO [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (47,059)        
Non-PEO NEO [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 64,690